# A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab

> **NCT01338558** · PHASE3 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** bevacizumab [Avastin]
- **DRUG:** cetuximab
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT01338558
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-06
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01338558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01338558, "A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01338558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*